More on Athersys (ATHX): Q1 misses on both EPS and revenue as total sales reflected a $2.4M...


More on Athersys (ATHX): Q1 misses on both EPS and revenue as total sales reflected a $2.4M decrease in Pfizer contract revenues. Net losses more than doubled over the period, as fair value of warrant liabilities resulted in an expense of $2.6M due to the re-pricing and increases in share price. Shares -3.3% AH.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs